Scientific deep-dive
SMART Trial: Semaglutide 2.4 mg in Kidney Disease Without Diabetes
Semaglutide 2.4 mg cut urine albumin by 52.1% vs placebo at 24 weeks in 101 adults with chronic kidney disease, excess weight, and no diabetes. Here is what SMART shows, why it is not proof of protection from kidney failure, and how it fits with FLOW and SELECT.
In adults with chronic kidney disease (CKD), overweight or obesity, and no diabetes, semaglutide 2.4 mg weekly cut urine albumin by 52.1% vs placebo at 24 weeks (95% CI −65.5 to −33.4) in the 101-person SMART trial[1]. That is a large effect on a lab marker, not proof of protection from kidney failure: SMART was too small and too short to measure kidney failure, and it is the closest randomized evidence for a group that the FLOW outcomes trial did not enroll[1][2].
Who SMART enrolled
SMART was an investigator-initiated, double-blind trial at 14 centers in the Netherlands, Germany, Spain, and Canada, funded by a research grant from Novo Nordisk[3]. It required an eGFR of at least 25, a urine albumin-to-creatinine ratio (UACR) of 30 to 3,500 mg/g, and a BMI of at least 27, and it excluded diabetes[1][3]. Participants were randomized to semaglutide 2.4 mg (n = 51) or placebo (n = 50), with the dose stepped up from 0.25 mg over 16 weeks[1][3].
At baseline, median UACR was 251 mg/g, mean eGFR was 65.0, and mean BMI was 36.2[1]. Most participants were already on standard kidney treatment: 86% took a renin-angiotensin system inhibitor and 19% an SGLT2 inhibitor[3]. Despite the trial’s focus on weight, the causes of CKD were mixed. Hypertensive CKD (27 people) and chronic glomerulonephritis (25) were the most common, and obesity-related glomerulopathy accounted for 10[1][3]. With so few in that last category, the trial speaks to CKD in people who also carry excess weight, not specifically to CKD caused by it. Participants were also 91% White and mostly men, and the authors say the results cannot be generalized to other populations[3].
Limits of what is reported here
The primary SMART results come from the abstract of the Nature Medicine paper, which does not name an estimand, so we cannot say whether −52.1% is a treatment-regimen or on-treatment figure. The body composition details come from the full text of the later secondary analysis, which used all randomized participants in a repeated-measures model[1][3].
What a 52% albumin drop does and does not mean
Urine albumin is a central biomarker for detecting CKD and judging its prognosis, and its change on treatment is a candidate surrogate endpoint for kidney failure[4]. A 2026 individual-participant meta-analysis of 48 randomized trials and 85,681 people found that each 30% reduction in UACR was associated with an average 19% lower hazard of kidney failure or doubled creatinine (95% credible interval 5 to 30), with no clear variation by cause of CKD[4]. An earlier analysis found the link less certain in people with low baseline albuminuria[5]. Those models cover trial-level averages across many treatments. They do not let anyone convert SMART’s result into a predicted drop in kidney failure for semaglutide.
GFR itself did not change significantly from baseline in the 24-week window, whether estimated from creatinine or cystatin C or measured with iohexol in a 47-person subgroup[3]. The authors note that GFR decline was minimal over the period, so SMART could not test whether semaglutide slows loss of kidney function[3].
How SMART compares with the larger semaglutide trials
These trials differ in population, dose, and endpoint, so the numbers should not be lined up as if measuring the same thing[1][2][6].
| SMART | FLOW | SELECT kidney analysis | |
|---|---|---|---|
| Population | CKD, BMI ≥27, no diabetes | Type 2 diabetes and CKD | Overweight or obesity, cardiovascular disease, no diabetes |
| Semaglutide dose | 2.4 mg weekly | 1.0 mg weekly | 2.4 mg weekly |
| Randomized | 101 | 3,533 | 17,604 |
| Follow-up | 24 weeks | Median 3.4 years | Long-term; eGFR reported at 104 weeks |
| Main kidney measure | Change in UACR | Kidney failure, ≥50% eGFR fall, or kidney or cardiovascular death | Kidney death, kidney replacement, eGFR <15, ≥50% eGFR fall, or macroalbuminuria |
| Result vs placebo | −52.1% (−65.5 to −33.4) | HR 0.76 (0.66 to 0.88) | HR 0.78 (0.63 to 0.96) |
SELECT comes nearest to SMART’s population by dose and absence of diabetes, but it enrolled people for cardiovascular disease and not for CKD, and its composite was uncommon: 1.8% vs 2.2%[6]. Its eGFR benefit at 104 weeks was 0.75 overall and 2.19 mL/min/1.73 m² in those starting below an eGFR of 60[6]. A Novo Nordisk funded pooled analysis of SELECT, FLOW, and SOUL (30,787 participants with and without diabetes, at doses of 1.0 mg, 2.4 mg, and oral 14 mg) reported a hazard ratio of 0.84 (95% CI 0.77 to 0.91) for a kidney composite that includes cardiovascular death[7]. It is not an estimate specific to people without diabetes. These results raise the plausibility of kidney benefit outside diabetes, without testing it directly in SMART’s population.
Kidney function tests stayed interpretable
A practical worry with large weight loss is that creatinine-based eGFR may look better simply because muscle mass fell. The prespecified 2026 SMART analysis looked for this. Between-group weight change was −9.1 kg (95% CI −11.0 to −7.2), yet changes in weight, lean mass, and fat mass did not correlate with changes in creatinine eGFR, cystatin C eGFR, or measured GFR (all Spearman coefficients below 0.23)[3]. The authors conclude that weight loss of about 10% with semaglutide does not influence GFR estimates[3]. That is a separate question from the early eGFR dip some people see on a GLP-1. The result cannot be generalized to people with fast GFR decline, the authors caution[3].
Lean mass: a less clear signal than the summary suggests
The abstract says semaglutide reduced both lean and fat mass, but the intervals are wide: −2.5 kg lean mass (95% CI −6.6 to 1.6) and −3.9 kg fat mass (95% CI −7.8 to 0.0) vs placebo[3]. The lean interval crosses zero and the fat interval touches it. Bioimpedance also counts bone and organs as lean mass, and muscle volume and physical performance were not measured[3]. The authors still advise pairing treatment with age-adjusted resistance exercise and appropriate nutrition, citing guideline recommendations[3].
Blood pressure and fluid
Semaglutide lowered systolic blood pressure by 6.3 mm Hg (95% CI −10.9 to −1.7) and extracellular water by 0.9 L (95% CI −1.6 to −0.1) vs placebo, and in the semaglutide arm the two changes moved together (Spearman coefficient about 0.4)[3]. Diastolic pressure did not change[3]. The authors suggest a possible natriuretic or diuretic effect but did not measure urinary sodium and call the findings hypothesis generating[3]. Weight and body composition effects also had not plateaued by 24 weeks[3].
Safety in a kidney population
Gastrointestinal adverse events were reported in 30 participants on semaglutide and 15 on placebo[1]. A 101-person, 24-week trial cannot rule out uncommon harms. For people already living with CKD, one warning in the Wegovy label deserves particular attention[8]:
There have been postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with semaglutide.— Wegovy prescribing information, Warnings and Precautions 5.5
The label adds that most reported events occurred in patients whose gastrointestinal effects led to dehydration, and it advises monitoring kidney function when such reactions occur[8].
Reviews and observational data: read with care
- A meta-analysis with thin inputs. A 2026 review pooled just 3 studies (430 participants), a randomized trial, an observational dialysis study, and a post hoc analysis, with fixed-effect models, and concluded the data support expanded use[9]. Studies this different in design cannot carry a conclusion that broad.
- A broader meta-analysis. Pooling 5 randomized trials with 12,785 people with CKD, with or without diabetes, gave a risk ratio of 0.79 (95% CI 0.71 to 0.87) for major kidney events. Its authors say further research is needed to confirm effects in non-diabetic CKD[10].
- Registry comparisons. In adults with obesity and no diabetes, a target trial emulation linked GLP-1 drugs to lower major kidney events than other anti-obesity medicines (HR 0.64, 95% CI 0.55 to 0.74)[11]. A semaglutide-specific cohort reported hazard ratios of 0.47 and 0.48 vs naltrexone-bupropion and phentermine-topiramate, though lab differences in creatinine and eGFR were limited[12]. These are associations, neither study was limited to CKD, and people who can get newer drugs may differ in ways matching cannot capture.
Where this leaves patients with CKD and no diabetes
The Ozempic label’s kidney indication is limited to adults with type 2 diabetes and CKD[13]. The Wegovy label, which includes the 2.4 mg dose SMART used, covers cardiovascular risk reduction, weight management, and a liver indication, with no kidney indication[8]. So for now, someone with non-diabetic CKD would generally be considered for semaglutide on weight or cardiovascular grounds, with albumin reduction as a possible added benefit that remains unconfirmed against hard outcomes.
The drugs with direct outcome evidence here are SGLT2 inhibitors. Dapagliflozin in DAPA-CKD (HR 0.61, 95% CI 0.51 to 0.72) and empagliflozin in EMPA-KIDNEY (HR 0.72, 95% CI 0.64 to 0.82) each reduced their kidney and cardiovascular composite, with similar or consistent effects in people without diabetes[14][15]. Those endpoints differ from SMART’s and no head-to-head test exists, but the distinction helps when weighing SGLT2 inhibitors against GLP-1 drugs.
Questions worth bringing to a nephrologist:
- Am I already on the treatments with outcome evidence for my type of CKD, and would semaglutide be added to them or replace something?
- Is my main reason for this drug weight, cardiovascular risk, or albuminuria, and how would we judge whether it is working?
- How often should UACR and kidney function be checked during dose increases, and what should I do if vomiting or diarrhea keeps me from staying hydrated?
- Does my cause of CKD resemble the people in SMART? Only 10 had obesity-related glomerulopathy, so results for that cause alone are thin[3].
Our reviews
Providers that offer semaglutide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.6. Read our review of Sprout HealthLegitScript-certified compounded GLP-1 via named pharmaciesFrom$99/mo12-month plan ratecompounded
- Editorial score: 7.5. Read our review of Luvo HealthCompounded and brand GLP-1s, oral tablets and microdosing on one public price listFrom$179/4 wksbilled per 4 weekscompounded
- Editorial score: 7.4. Read our review of BrightmedsCompounded or brand GLP-1 bundled with TRT and peptides for menFrom$129/mocompounded
- Editorial score: 7.4. Read our review of altRXLow-cost compounded GLP-1s with brand-name Zepbound, Wegovy and Ozempic as optionsFrom$89/mocompounded
- Editorial score: 7.4. Read our review of MadeMedCompounded GLP-1 in both injection and oral formsFrom$179/mocompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Apperloo EM, Gorriz JL, Soler MJ, Cigarrán Guldris S, Cruzado JM, Puchades MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025. PMID: 39455729.
- 2.Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. PMID: 38785209.
- 3.Heerspink HJL, Soler M, Beernink JM, Jongs N, Cigarran S, Cruzado JM, et al. Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial. Clin J Am Soc Nephrol. 2026. PMID: 42308057.
- 4.Heerspink HJL, Collier WH, Chaudhari J, Miao S, Tighiouart H, Appel GB, et al. A meta-analysis of albuminuria as a surrogate endpoint for kidney failure. Nat Med. 2026. PMID: 41198855.
- 5.Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019. PMID: 30635226.
- 6.Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024. PMID: 38796653.
- 7.Mann JFE, Badve SV, Baeres FMM, Belmar N, Brown-Frandsen K, Buse JB, et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. Lancet Diabetes Endocrinol. 2026. PMID: 42567173.
- 8.Novo Nordisk. WEGOVY (semaglutide) injection and tablets. Prescribing information. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 9.Elganyny MKE, Elganyni AKE, Maskji HA, Ajaka N, Mishriki AES, Amin RSK, et al. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis. Clin Ter. 2026. PMID: 42340790.
- 10.Abdullah A, Sagreeka FNU, Aniket GA, Lal R, Geeta FNU, Bai A, et al. Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2025. PMID: 41276951.
- 11.Tang H, Lu Y, Zhang B, Zhou T, Zhang D, Chen J, et al. Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes Obes Metab. 2025. PMID: 40874398.
- 12.Chen SC, Liu KW, Huang YN, Meyerowitz-Katz G, Su PH. Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes. Am J Ther. 2026. PMID: 41992281.
- 13.Novo Nordisk. OZEMPIC (semaglutide) injection. Prescribing information. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- 14.Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020. PMID: 32970396.
- 15.The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023. PMID: 36331190.
Related research
FLOW Trial: Semaglutide Kidney Subgroup Detail (2026)
A deep dive into the FLOW trial secondary analyses: eGFR slope, cardiovascular and all-cause death, heart failure, and benefit across CKD severity, SGLT2i, and MRA subgroups.
13 min read
FLOW Trial Update: GLP-1 for CKD Stage 3-4 — The Evidence
Semaglutide reduced major kidney events by 24% in FLOW. We review the eGFR slope, the practical CKD prescribing protocol, the dialysis-imminent patient pathway, and how SURPASS-MULTI shapes tirzepatide's renal positioning.
12 min read
GLP-1 with Kidney Disease (CKD): The Patient Action Plan
If you have CKD and your clinician is considering a GLP-1, here is what changed: FLOW trial Perkovic 2024 NEJM 24% kidney + CV event reduction, AWARD-7 dulaglutide in moderate-severe CKD, no renal dose adjustment for most GLP-1s, sick-day rules with SGLT2 + ACE-I.
14 min read
Retatrutide and kidney protection: Phase 2 post-hoc evidence and TRANSCEND-CKD
Retatrutide is investigational and not FDA-approved. Heerspink 2025 Kidney Int Rep post-hoc Phase 2: 12 mg cut UACR -37% at 36 wk in T2D; 8/12 mg raised eGFR +5.3/+8.5 mL/min/1.73 m2 in obesity at 48 wk. TRANSCEND-CKD Phase 2b (n=146) results not yet published.
19 min read
'Wegovy Penis' Explained: Un-Burying, Better Erections & Rising Testosterone
Wegovy penis is optics and circulation, not a drug acting on the organ: true length is fixed, but buried shaft is uncovered as the suprapubic fat pad shrinks. Erections and testosterone may improve, though no randomized GLP-1 trial has tested them.
9 min read
Best Time of Day to Take Semaglutide: Morning or Night? (2026)
Injectable semaglutide (Ozempic, Wegovy) can be taken any time of day, with or without food — same day each week is what matters. Rybelsus is the strict morning exception.
6 min read
Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
From $139/mo (4-month plan rate)
Get started →HumeCare+
GLP-1 weight loss with real-time body-composition tracking to protect muscle
Read full review →From $199/mo
Get started →Collective
The lowest flat medication price if you can absorb an annual membership fee
Read full review →From $59/mo (+ required membership)
Get started →